medical devices
IDG backs China surgical robot start-up
IDG Capital has joined a Series A round of several hundred million renminbi for China’s Sustao, which is developing a platform for fully automating surgical robots.
Vision Fund backs Japan's AI Medical Service
SoftBank Vision Fund 2 has led a JPY 8bn (USD 70m) Series C funding round for AI Medical Service, a Tokyo-based medical technology company that has developed an artificial intelligence-enabled (AI) endoscopy diagnostic solution.
Australia's Saluda Medical raises $125m
US-based healthcare investor Redmile Group has led a USD 125m round for Australia’s Saluda Medical, a devices company focused on spinal cord stimulation.
Warburg Pincus commits $210m to India medical devices business
Warburg Pincus has acquired a minority interest in Micro Life Sciences, the parent company of India-headquartered medical devices manufacturer Meril, for approximately USD 210m.
Singapore's Virtue Diagnostics closes $100m Series B
Singapore-based Virtue Diagnostics, a clinical testing equipment supplier for China and developing markets, has raised a USD 100m Series B round led by Sequoia Capital China and Morningside Ventures.
PEP sells Australia, New Zealand healthcare businesses
Pacific Equity Partners (PEP) has agreed two healthcare exits, with Australia-based medical devices distributor LifeHealthcare to be sold to Ebos Group and New Zealand corporate hospital platform Evolution Healthcare going to QIC and Sunsuper.
China surgical robotics player RainMed raises $100m
Ping An Capital has led a Series D round of approximately $100 million for RainMed Medical, a China-based surgical robotics business. Other investors include Seresia Asset Management and Lighthouse Canton.
Pencarrow makes New Zealand clinical research investments
Pencarrow Private Equity has invested in two of New Zealand’s leading clinical research companies, combining them into a single entity in which it holds a 52.3% stake.
Alibaba leads Series D for China cancer test kit business
Guangzhou-based Creative Biosciences, which manufacturers kits that test for colon cancer, has raised a RMB560 million ($88 million) Series D led by Alibaba Group.